Brightstar Capital Partners Acquires Analyte Health, Establishing Platform in Direct-to-Consumer Healthcare

NEW YORK & HOUSTON--(BUSINESS WIRE)--Brightstar Capital Partners (“Brightstar”), a private equity firm focused on investing in business services, industrials, consumer, and government services and technology companies, announced today that it has acquired Analyte Health (“Analyte” or the “Company”), a technology-driven, direct-to-consumer digital health company. As part of the transaction, Analyte founder Fiyyaz Pirani will continue as CEO and retain a significant ownership stake in the Company.

Analyte Health provides discreet, high-quality diagnostic and treatment services across key consumer wellness categories. Powered by a proprietary technology stack and supported by a national network of partner laboratories and physicians, Analyte delivers an integrated experience spanning clinical testing, virtual care, and prescription fulfillment. The Company has served millions of patients across the U.S. and continues to expand its offering across wellness, sexual health, and hormonal therapies.

“This partnership marks an exciting new chapter for us, as Brightstar brings both strategic expertise and a deep respect for the culture and customer trust we’ve built,” said Fiyyaz Pirani, CEO of Analyte. “I’m confident Brightstar’s operational resources and investment will help us scale while staying true to our mission of providing accessible, high-quality care directly to the consumer. I’m proud to continue leading the Company forward and remain fully committed as a significant shareholder.”

“We are thrilled to welcome Analyte to the Brightstar portfolio,” said Michael Singer, Partner at Brightstar. “Analyte is a purpose-built platform at the intersection of healthcare, technology, and consumer engagement—segments we think are poised for long-term growth.”

“With a strong founder, compelling unit economics, and multiple avenues for expansion, we believe there is a significant opportunity to build a leading brand in direct-to-consumer digital healthcare,” added Sam Totusek, Managing Director at Brightstar.

J.P. Morgan Securities LLC served as exclusive financial advisor and Kirkland & Ellis LLP served as legal advisor to Brightstar. Intrepid Investment Bankers LLC served as financial advisor and Kastner Gravelle LLP as legal advisor to Analyte in connection with the transaction.

About Analyte Health

Analyte Health is a digital health company delivering direct-to-consumer diagnostics and treatment. Leveraging a scalable platform that integrates clinical testing, virtual care, and prescription fulfillment, the Company offers an accessible, confidential, and patient-centered experience across a range of healthcare categories. Analyte is headquartered in Houston, Texas. For more information, please visit www.analytehealth.com.

About Brightstar Capital Partners

Brightstar Capital Partners is a middle market private equity firm with $5 billion in AUM that is focused on investing in business services, industrials, consumer, and government services and technology companies, where Brightstar believes it can drive significant value with respect to the management, operations, and strategic direction of the business. Since its founding in 2015, Brightstar has accumulated extensive experience partnering with family, founder, or entrepreneur-led businesses. Brightstar employs an operationally intensive “Us & Us” approach that leverages its considerable hands-on operational expertise and deep relationship network to help companies reach their full potential. For more information, please visit www.brightstarcp.com.